Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 2
2012 3
2013 8
2014 4
2015 10
2016 3
2017 5
2018 3
2019 3
2020 6
2021 7
2022 12
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of a first-in-class EZH2 selective degrader.
Ma A, Stratikopoulos E, Park KS, Wei J, Martin TC, Yang X, Schwarz M, Leshchenko V, Rialdi A, Dale B, Lagana A, Guccione E, Parekh S, Parsons R, Jin J. Ma A, et al. Among authors: lagana a. Nat Chem Biol. 2020 Feb;16(2):214-222. doi: 10.1038/s41589-019-0421-4. Epub 2019 Dec 9. Nat Chem Biol. 2020. PMID: 31819273 Free PMC article.
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, Bhalla S, Scholler N, Bot A, Rossi JM, Sadek N, Parekh S, Lagana A, Baccarini A, Merad M, Brown BD, Brody JD. Upadhyay R, et al. Among authors: lagana a. Cancer Discov. 2021 Mar;11(3):599-613. doi: 10.1158/2159-8290.CD-20-0756. Epub 2020 Dec 17. Cancer Discov. 2021. PMID: 33334730 Free PMC article.
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, Kim-Schulze S, Rahman A, Laganà A, Brody JD, Merad M, Jagannath S, Parekh S. Van Oekelen O, et al. Among authors: lagana a. Nat Med. 2021 Dec;27(12):2099-2103. doi: 10.1038/s41591-021-01564-7. Epub 2021 Dec 10. Nat Med. 2021. PMID: 34893771 Free PMC article.
The genome of IMiD-refractory myeloma.
Laganà A. Laganà A. Blood. 2023 Feb 9;141(6):560-561. doi: 10.1182/blood.2022018461. Blood. 2023. PMID: 36757732 Free article. No abstract available.
Artificial Intelligence for Precision Oncology.
Bhalla S, Laganà A. Bhalla S, et al. Among authors: lagana a. Adv Exp Med Biol. 2022;1361:249-268. doi: 10.1007/978-3-030-91836-1_14. Adv Exp Med Biol. 2022. PMID: 35230693 Review.
(Distinct) origins of IgM myeloma.
Laganà A, Parekh S. Laganà A, et al. Blood. 2021 Nov 18;138(20):1914-1915. doi: 10.1182/blood.2021013860. Blood. 2021. PMID: 34792568 Free article. No abstract available.
Multi-Omics Profiling of the Tumor Microenvironment.
Van Oekelen O, Laganà A. Van Oekelen O, et al. Among authors: lagana a. Adv Exp Med Biol. 2022;1361:283-326. doi: 10.1007/978-3-030-91836-1_16. Adv Exp Med Biol. 2022. PMID: 35230695
Asciminib as a third line option in chronic myeloid leukemia.
Laganà A, Scalzulli E, Carmosino I, Martelli M, Breccia M. Laganà A, et al. Int J Hematol. 2023 Jan;117(1):16-23. doi: 10.1007/s12185-022-03432-7. Epub 2022 Aug 5. Int J Hematol. 2023. PMID: 35930119 Review.
74 results